CHDI
PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease
European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options RG6042 has th ...Read More
PTC Therapeutics and CHDI Foundation Announce a Collaboration on a Small-Molecule Therapeutic for Huntington’s Disease
SOUTH PLAINFIELD, N.J., April 4, 2018 – PTC Therapeutics, Inc. (NASDAQ: PTCT) and the CHDI Foundation, Inc. (CHDI) today announced a research collaboration to advance PTC’s Huntington’s disease program. The program is optimizin ...Read More
C-Path and CHDI launch consortium to accelerate development of Huntington’s disease therapies
Tucson, AZ, and New York, NY – March 28, 2018 – The Critical Path Institute (C-Path), together with CHDI Foundation, Inc. (CHDI), today announced the off ...Read More
Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington’s Disease
Dose-dependent Reductions of Mutant Huntingtin Protein Observed Ionis Earns $45 Million License Fee CARLSBAD, Calif., Dec. 11, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Roche has exercis ...Read More
13th Annual HD Therapeutics Conference
CHDI is delighted to announce that the 13th Annual HD Therapeutics Conference will be held February 26-March 1, 2018, in Palm Springs, California. The conference program is currently being crafted and will cover all aspects of drug discovery related ...Read More
C-Path, CHDI Foundation, and CDISC Announce Public Review Period for Huntington’s Disease Therapeutic Area User Guide
TUCSON, AZ, NEW YORK, NY, and AUSTIN, TX – September 11, 2017 – Critical Path Institute (C-Path), ...Read More
HudsonAlpha and CHDI Foundation announce Huntington disease collaboration
Project will study gene regulatory network of genetic neurodegenerative disorder Huntsville, Ala. — HudsonAlpha Institute for Biotechnology ...Read More
Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington’s Disease Completed and Open-Label Extension Study to Open in 2H 2017
CARLSBAD, Calif., June 22, 2017 -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the completion of enrollment in the Phase 1/2a randomized, placebo-controlled, dose escalation study of IONIS-HTTRx in patients ...Read More
Voyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease
VY-HTT01 Selection Based on Robust Knockdown of Huntingtin in Preclinical Studies Program On Track for IND Filing in 2018
Cambridge, Mass., June 1, 2017 – Voyager Therapeutics, I ...Read More12th Annual HD Therapeutics Conference
Coming soon… online hosting of the presentations from the Malta conference. ...Read More